Literature DB >> 22653741

Presence of CSE1L protein in urine of patients with urinary bladder urothelial carcinomas.

Cheng-Jeng Tai1, Ching-Fong Liao, Tzu-Cheng Su, Ko-Hung Shen, Chun-Chao Chang, Shu-Hui Lin, Chung-Min Yeh, Shing-Chuan Shen, Woan-Ruoh Lee, Jeng-Fong Chiou, Chih-Hung Lin, Ying-Chun Chen, Hsin-Yi Shih, Kun-Tu Yeh, Ming-Chung Jiang.   

Abstract

The chromosome segregation 1-like (CSE1L) protein is highly expressed in most cancers and has been shown to be secreted by tumor cells. We studied the presence of CSE1L in the urine of patients with bladder urothelial carcinomas. The results of our immunohistochemical analysis showed a high expression of CSE1L in bladder cancer specimens, while the normal bladder specimens only showed a very faint staining in some cells. Immunoblotting showed that CSE1L was present in urine of patients with bladder cancer. Urinary CSE1L-positive cases were detected in 95% (57/60) of patients with bladder urothelial carcinomas or the atypical/suspicious cases with urothelial atypia. No CSE1L was detected in urine of healthy controls (p<0.01). Our results suggest that urinary CSE1L deserves further evaluation for the screening of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22653741     DOI: 10.5301/JBM.2012.9310

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  5 in total

Review 1.  CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy.

Authors:  Ming-Chung Jiang
Journal:  Tumour Biol       Date:  2016-09-05

2.  CSE1L, a novel microvesicle membrane protein, mediates Ras-triggered microvesicle generation and metastasis of tumor cells.

Authors:  Ching-Fong Liao; Shu-Hui Lin; Hung-Chang Chen; Cheng-Jeng Tai; Chun-Chao Chang; Li-Tzu Li; Chung-Min Yeh; Kun-Tu Yeh; Ying-Chun Chen; Tsu-Han Hsu; Shing-Chuan Shen; Woan-Ruoh Lee; Jeng-Fong Chiou; Shue-Fen Luo; Ming-Chung Jiang
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

3.  Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.

Authors:  Woan-Ruoh Lee; Shing-Chuan Shen; Yi-Hsien Shih; Chia-Lun Chou; Jonathan Te-Peng Tseng; Szu-Ying Chin; Kao-Hui Liu; Yen-Chou Chen; Ming-Chung Jiang
Journal:  J Transl Med       Date:  2015-06-13       Impact factor: 5.531

4.  FLVCR1 Predicts Poor Prognosis and Promotes Malignant Phenotype in Esophageal Squamous Cell Carcinoma via Upregulating CSE1L.

Authors:  Suna Zhou; Mingxin Zhang; Chao Zhou; Yinnan Meng; Haihua Yang; Wenguang Ye
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

5.  Correlations between cytoplasmic CSE1L in neoplastic colorectal glands and depth of tumor penetration and cancer stage.

Authors:  Cheng-Jeng Tai; Tzu-Cheng Su; Ming-Chung Jiang; Hung-Chang Chen; Shing-Chuan Shen; Woan-Ruoh Lee; Ching-Fong Liao; Ying-Chun Chen; Shu-Hui Lin; Li-Tzu Li; Ko-Hung Shen; Chung-Min Yeh; Kun-Tu Yeh; Ching-Hsiao Lee; Hsin-Yi Shih; Chun-Chao Chang
Journal:  J Transl Med       Date:  2013-01-31       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.